Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.17 USD | +1.77% | -2.35% | +1.46% |
05:34pm | Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study | MT |
May. 06 | Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000 | MT |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Press Releases